Scott Thomas, PhD
Associate Researcher
Medicine
School of Medicine

Education & Training

Show all (2) Hide

• PhD Biochemistry, Cell, and Molecular Biology University of California, Davis
• Postdoctoral Studies Graduate Division University of California, San Francisco

Websites

Show all (2) Hide

• Alessa Therapeutics (alessatherapeutics.com)
• Munster Laboratory (munster.ucsf.edu)

Publications (30)

Top publication keywords:
Hydroxamic AcidsKinetochoresEstrogen Receptor ModulatorsEstrogen AntagonistsHistone DeacetylasesBreast NeoplasmsMammaplastyAntineoplastic Agents, HormonalIndolesEstradiolTamoxifenHistone Deacetylase InhibitorsSelective Estrogen Receptor ModulatorsReceptors, EstrogenEpirubicin

• A long-term fulvestrant eluting implant is safe, non-toxic, and reduces the risk of breast cancer in in vivo models.
  Research square 2023 Thomas S, Roche E, Desai P, Pawlowska N, Bauer D, Gingrich D, Hsu E, Deitchman AN, Aweeka F, Munster PN
• A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
  Cancer research communications 2022 Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN
• The effect of marrow secretome and culture environment on the rate of metastatic breast cancer cell migration in two and three dimensions.
  Molecular biology of the cell 2021 Curtis KJ, Mai C, Martin H, Oberman AG, Alderfer L, Romero-Moreno R, Walsh M, Mitros SF, Thomas SG, Dynako JA, Zimmer DI, McNamara LM, Littlepage LE, Niebur GL
• Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.
  Nature communications 2020 Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN
• Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Wieduwilt MJ, Pawlowska N, Thomas S, Olin R, Logan AC, Damon LE, Martin T, Kang M, Sayre PH, Boyer W, Gaensler KML, Anderson K, Munster PN, Andreadis C

Show all (25 more) Hide

• Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer.
  Scientific reports 2018 Park J, Thomas S, Zhong AY, Wolfe AR, Krings G, Terranova-Barberio M, Pawlowska N, Benet LZ, Munster PN
• HDAC inhibition potentiates immunotherapy in triple negative breast cancer.
  Oncotarget 2017 Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, Rosenblum MD, Budillon A, Munster PN
• Host histone acetylation unlocks HDAC inhibitor potential.
  Oncotarget 2017 Terranova-Barberio M, Thomas S, Munster PN
• Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
  Breast cancer research : BCR 2017 Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, …
• Autologous Fat Grafting as a Novel Antiestrogen Vehicle for the Treatment of Breast Cancer.
  Plastic and reconstructive surgery 2017 Thomas S, Chen S, Sbitany H, Kwon E, Piper M, Park J, Terranova Barberio M, Pawlowska N, Munster PN
• Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN
• Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN
• Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
  Immunotherapy 2016 Terranova-Barberio M, Thomas S, Munster PN
• A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
  Annals of oncology : official journal of the European Society for Medical Oncology 2016 Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN
• Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
  Breast cancer research : BCR 2015 Raha P, Thomas S, Thurn KT, Park J, Munster PN
• Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
  Epigenomics 2015 Park J, Thomas S, Munster PN
• Histone deacetylase regulation of ATM-mediated DNA damage signaling.
  Molecular cancer therapeutics 2013 Thurn KT, Thomas S, Raha P, Qureshi I, Munster PN
• Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt.
  PloS one 2013 Thomas S, Thurn KT, Raha P, Chen S, Munster PN
• Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance.
  Epigenomics 2011 Raha P, Thomas S, Munster PN
• A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.
  British journal of cancer 2011 Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE
• Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy.
  Breast cancer research and treatment 2011 Thomas S, Thurn KT, Biçaku E, Marchion DC, Münster PN
• Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.
  Future oncology (London, England) 2011 Thurn KT, Thomas S, Moore A, Munster PN
• Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
  British journal of cancer 2009 Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A
• Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
  Cancer letters 2009 Thomas S, Munster PN
• A Bir1p Sli15p kinetochore passenger complex regulates septin organization during anaphase.
  Molecular biology of the cell 2007 Thomas S, Kaplan KB
• A novel role for the CBF3 kinetochore-scaffold complex in regulating septin dynamics and cytokinesis.
  The Journal of cell biology 2005 Gillis AN, Thomas S, Hansen SD, Kaplan KB
• Sgt1p and Skp1p modulate the assembly and turnover of CBF3 complexes required for proper kinetochore function.
  Molecular biology of the cell 2004 Rodrigo-Brenni MC, Thomas S, Bouck DC, Kaplan KB
• Eukaryotic glycosyltransferases: cysteines and disulfides.
  Glycobiology 2002 Thomas S, Yen TY, Macher BA
• Human alpha 1,3/4 fucosyltransferases. Characterization of highly conserved cysteine residues and N-linked glycosylation sites.
  The Journal of biological chemistry 2000 Holmes EH, Yen TY, Thomas S, Joshi R, Nguyen A, Long T, Gallet F, Maftah A, Julien R, Macher BA
• A historically controlled trial of tyrosine for cocaine dependence.
  Journal of psychoactive drugs 1996 Galloway GP, Frederick SL, Thomas S, Hayner G, Staggers FE, Wiehl WO, Sajo E, Amodia D, Stewart P